[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | Sponsor | E-mail ]

Turkish Journal of Cancer
2008, Volume 38, Number 2, Page(s) 049-056
[ Summary ] [ Full Text ] [ PDF ]
The role of microsatellite instability to predict clinical benefit from irinotecan-based regimens in metastatic colorectal cancer
MEHMET ARTAÇ1, SACİDE PEHLİVAN2, SONGÜL AKCAN3, MUSTAFA PEHLİVAN4, TEKİNALP GELEN5, GÜLÇİN ITIRLI6, NAZİF AKSOY5, MUSTAFA ÖZDOĞAN7, BURHAN SAVAŞ7, MUSTAFA SAMUR7, HAKAN BOZCUK7
1 Selçuk University Meram Medical Faculty, Department of Medical Oncology, Konya
2 Gaziantep University Medical Faculty, Department of Medical Biology, Gaziantep
3 Akdeniz University Medical Faculty, Department of Internal Medicine, Antalya
4 Gaziantep University Medical Faculty, Department of Hematology, Gaziantep
5 Akdeniz University Medical Faculty, Department of Pathology, Antalya
6 Ege University Science Faculty, Department of Biology, İzmir
7 Akdeniz University Medical Faculty, Department of Medical Oncology, Antalya-Turkey
The aim of our study was to assess the relationship between microsatellite instability (MSI) and the clinical outcome in metastatic colorectal cancer (CRC) patients treated with irinotecan-based regimens. We assessed best objective response, progression free survival (PFS) and overall survival (OAS) in relation to MSI analysis that was performed using BAT-25, BAT-26, D5S346, D2S123, D17S250 markers in normal and tumor DNA. The best objective response was significantly and negatively related with the D17S250 (an adjacent locus to p53) microsatellite marker (p=0.047). However, MSI score was not related with the best objective response (p=0.88). There was again no relationship between PFS, OAS and MSI score. In conclusion, this study allowed us to establish in a prospective study design that MSI status did not predict survival in metastatic colorectal cancer patients treated with irinotecan-based regimens. [Turk J Cancer 2008;38(2):49-56]
[ Summary ] [ Full Text ] [ PDF ]
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]